21512-16-3

Usage

Uses

Used in Pest Control:
5-CYANO-2-THIOPHENE CARBALDEHYDE is used as a bioactive compound for pest control, particularly against Meloidogyne incognita, a type of root-knot nematode that causes significant damage to agricultural crops. Its presence in caper plants suggests that it may have potential as a natural pesticide or repellent.
Used in Pharmaceutical Industry:
Although not explicitly mentioned in the provided materials, 5-CYANO-2-THIOPHENE CARBALDEHYDE could potentially be used as a building block or intermediate in the synthesis of various pharmaceutical compounds due to its unique chemical structure. Its cyano and formyl groups can be further modified or reacted to create a wide range of molecules with different biological activities.
Used in Chemical Synthesis:
5-CYANO-2-THIOPHENE CARBALDEHYDE can be utilized as a key intermediate in the synthesis of various organic compounds, such as dyes, pigments, and other specialty chemicals. Its reactivity and functional groups make it a versatile starting material for the development of new molecules with specific properties and applications.
Used in Flavor and Fragrance Industry:
Given its presence in caper plants, 5-CYANO-2-THIOPHENE CARBALDEHYDE may also have potential applications in the flavor and fragrance industry. Its unique chemical structure could contribute to the development of new aroma compounds or enhance the sensory properties of existing products.

Upstream product

• 1003-31-2 thiophene-2-carbonitrile 
• 68-12-2 N,N-dimethyl-formamide 

Downstream Products

• 1437787-00-2 5-(((2,5-difluorobenzyl)(pyridin-3-ylmethyl)amino)methyl)-thiophene-2-carbonitrile 

Relevant academic research and scientific papers

TETRAZOLE DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS

This invention relates to novel tetrazole derivatives, which are found to be modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

Amine Compounds

There is provided a compound exhibiting an activity of suppressing immune response with reduced adverse drug reactions, which compound is useful in the chemotherapy for preventing or treating, for example, a wide range of various autoimmune diseases including systemic erythematodes, chronic rheumatoid arthritis, Type I diabetes, inflammatory bowel disease, biliary cirrhosis, uveitis, multiple sclerosis or other disorders, or chronic inflammatory diseases, or cancers, lymphoma or leukemia, or resistance to organ or tissue transplantation or rejection against transplantation. Novel amine compounds having an S1P1/Edg1 receptor agonist effect, possible stereoisomers or racemic bodies of the compounds, or pharmacologically acceptable salts, hydrates or solvates of the compound, the stereoisomers or the racemic bodies, or prodrugs of the compounds, the stereoisomers, the racemic bodies, the salts, the hydrates or the solvates, are provided.

Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade

The invention relates to substituted polycyclic aryl and heteroaryl pyrazinone compounds useful as inhibitors of serine proteases of the coagulation cascade and compounds, compositions and methods for anticoagulant therapy for the treatment and prevention of a variety of thrombotic conditions including coronary artery and cerebrovascular diseases.

ANTITHROMBOTIC AGENTS

This invention relates to thrombin inhibiting compounds having the Formula IX--Y--NH--(CH 2) r--G I where X, Y, r and G have the values defined in the description, as well as pharmaceutical formulations containing those compounds and methods of their use as thrombin inhibitors, coagulation inhibitors, and thromboembolic disorder agents.

ANTITHROMBOTIC AGENTS

This invention relates to thrombin inhibiting compounds having the FormulaIX--Y--NH--(CH 2) r--G I where X, Y, r and G have the values defined in the description, as well as pharmaceutical formulations containing those compounds and methods of their use as thrombin inhibitors, coagulation inhibitors, and thromboembolic disorder agents.

ANTITHROMBOTIC AGENTS

This invention relates to thrombin inhibiting compounds having the FormulaIX--Y--NH--(CH 2) r--G I where X, Y, r and G have the values defined in the description, as well as pharmaceutical formulations containing those compounds and methods of their use as thrombin inhibitors, coagulation inhibitors, and thromboembolic disorder agents.

ANTITHROMBOTIC AGENTS

This invention relates to thrombin inhibiting compounds having the FormulaIX--Y--NH--(CH 2) r--G I where X, Y, r and G have the values defined in the description, as well as pharmaceutical formulations containing those compounds and methods of their use as thrombin inhibitors, coagulation inhibitors, and thromboembolic disorder agents.

ANTITHROMBOTIC AGENTS

This invention relates to thrombin inhibiting compounds having the FormulaIX--Y--NH--(CH 2) r--G I where X, Y, r and G have the values defined in the description, as well as pharmaceutical formulations containing those compounds and methods of their use as thrombin inhibitors, coagulation inhibitors, and thromboembolic disorder agents.